CLARITY PHARMACEUTICALS LTD - Announcements

5.25%

$3.61

Market Cap $1.340B

Healthcare Biotechnology

Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical... Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing theranostic (therapy and imaging) products, based on its platform SAR Technology. It is progressing seven clinical trials with its three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2), including neuroblastoma and neuroendocrine tumors (NETs). SAR-bisPSMA is developed for diagnosing, staging, and treating cancers that express Prostate Specific Membrane Antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer. It has a diverse range of products in clinical trials, which address both large indications as well as rare and orphan indications of cancer.More

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care. LATEST: Race Oncology Accelerates Game-Changing Cancer Drug.

Announcements

Filter Results

All Price Sensitive Only

CU6	50% recruitment milestone reached for prostate cancer trial	PRICE SENSITIVE	27/10/22	311.17KB	Share
CU6	Notice of Annual General Meeting/Proxy Form		25/10/22	1.55MB	Share
CU6	Application for quotation of securities - CU6		13/10/22	25.78KB	Share
CU6	Notification of cessation of securities - CU6		12/10/22	22.96KB	Share
CU6	First patient treated in therapeutic prostate cancer trial	PRICE SENSITIVE	07/10/22	689.22KB	Share
CU6	First participant imaged in Phase II SAR-Bombesin trial	PRICE SENSITIVE	06/10/22	323.81KB	Share
CU6	Date of AGM		30/09/22	153.07KB	Share
CU6	Corporate Governance Annual Statement		15/09/22	824.96KB	Share
CU6	Annual Report to shareholders		15/09/22	14.36MB	Share
CU6	First participants imaged in SAR-Bombesin trial	PRICE SENSITIVE	14/09/22	319.77KB	Share
CU6	Radiopharmaceuticals Expert Joins Clarity as Chief Scientifi		13/09/22	197.96KB	Share
CU6	Clarity strengthens protection of the SAR-bisPSMA product		12/09/22	298.39KB	Share
CU6	Recruitment opens for Phase II trial in Prostate Cancer	PRICE SENSITIVE	05/09/22	334.84KB	Share
CU6	Preliminary Final Report	PRICE SENSITIVE	24/08/22	3.52MB	Share
CU6	Paediatric neuroblastoma trial advances to cohort 3	PRICE SENSITIVE	23/08/22	194.47KB	Share
CU6	Imaging trial in prostate cancer opens for recruitment	PRICE SENSITIVE	22/08/22	293.07KB	Share
CU6	Notification regarding unquoted securities - CU6		16/08/22	29.21KB	Share
CU6	Clarity expands manufacturing capabilities		11/08/22	172.73KB	Share
CU6	Clarity and Evergreen expand TCT manufacturing		09/08/22	181.89KB	Share
CU6	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/07/22	6.99MB	Share
CU6	Recruitment complete for diagnostic prostate cancer trial		20/07/22	663.89KB	Share
CU6	Notification of cessation of securities - CU6		07/07/22	21.69KB	Share
CU6	Change of Director's Interest Notice - Biggin		06/07/22	218.19KB	Share
CU6	Notification regarding unquoted securities - CU6		06/07/22	24.87KB	Share
CU6	Application for quotation of securities - CU6		06/07/22	25.12KB	Share
CU6	Application for quotation of securities - CU6		29/06/22	25.12KB	Share
CU6	Leading Australian cancer expert joins Clarity SAB		29/06/22	181.29KB	Share
CU6	Change of Director's Interest Notice O'Bryan-Tear		23/06/22	214.64KB	Share
CU6	Application for quotation of securities - CU6		22/06/22	25.91KB	Share
CU6	Release of Securities from Escrow		20/06/22	168.71KB	Share
CU6	Governance & Trading Policy Update		09/06/22	366.57KB	Share
CU6	IND Approval by US FDA for Phase II SAR-Bombesin trial	PRICE SENSITIVE	06/06/22	311.92KB	Share
CU6	Notification regarding unquoted securities - CU6		01/06/22	28.46KB	Share
CU6	Change of Director's Interest Notice - Thomas Ramdahl		01/06/22	214.18KB	Share
CU6	Change of Director's Interest Notice - Rob Thomas		31/05/22	212.77KB	Share
CU6	Clarity adds innovative nanobody IP		31/05/22	164.73KB	Share
CU6	Presentation Jefferies Biotech Summit	PRICE SENSITIVE	27/05/22	3.43MB	Share
CU6	Dr Neal Shore joins Clarity's CAB		26/05/22	160.38KB	Share
CU6	Clarity confirms no supply issues to its clinical trials		10/05/22	174.34KB	Share
CU6	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/04/22	6.73MB	Share
CU6	Cleansing Notice		21/04/22	182.51KB	Share
CU6	Application for quotation of securities - CU6		21/04/22	24.93KB	Share
CU6	First patient treated in the prostate cancer imaging trial	PRICE SENSITIVE	21/04/22	292.05KB	Share
CU6	Application for quotation of securities - CU6		14/04/22	25.7KB	Share
CU6	Notification of cessation of securities - CU6		14/04/22	22.47KB	Share
CU6	Dr Andrei Iagaru joins Clarity Scientific Advisory Board		05/04/22	158.74KB	Share
CU6	Appointment of CFO		04/04/22	156.75KB	Share
CU6	COBRA trial in prostate cancer opens for recruitment		28/03/22	202.62KB	Share
CU6	New clinical trial collaboration in prostate cancer		24/03/22	190.28KB	Share
CU6	Clarity - Investor Presentation 03-03-2022		03/03/22	4.37MB	Share
CU6	Clarity Half Yearly Report	PRICE SENSITIVE	28/02/22	7.02MB	Share
CU6	Half Year Accounts	PRICE SENSITIVE	28/02/22	1.35MB	Share
CU6	Update on China Grand Pharmaceutical and Healthcare Holdings	PRICE SENSITIVE	28/02/22	159.86KB	Share
CU6	First patient treated in cohort 2 neuroblastoma trial	PRICE SENSITIVE	25/02/22	184.55KB	Share
CU6	Release of Securities from Escrow		18/02/22	179.15KB	Share
CU6	US FDA Study May Proceed letter for Cu-64 SAR-bisPSMA	PRICE SENSITIVE	07/02/22	205.89KB	Share
CU6	Clarity receives $3.26 million R&D tax incentive refund	PRICE SENSITIVE	04/02/22	154.87KB	Share
CU6	Response to media reports of shortages of medical isotopes		03/02/22	185.69KB	Share
CU6	SARTATE Neuroblastoma trial advances to cohort 2	PRICE SENSITIVE	01/02/22	182.3KB	Share
CU6	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/22	5.67MB	Share
CU6	Becoming a substantial holder		12/01/22	248.26KB	Share
CU6	Change of Director's Interest Notice - Biggin		04/01/22	218.35KB	Share
CU6	Cleansing Notice		04/01/22	398.42KB	Share
CU6	Application for quotation of securities - CU6		04/01/22	25.71KB	Share
CU6	Becoming a substantial holder		30/12/21	180.88KB	Share
CU6	Application for quotation of securities - CU6		30/12/21	25.92KB	Share
CU6	Application for quotation of securities - CU6		29/12/21	25.92KB	Share
CU6	Release of Securities from Escrow		07/12/21	395.43KB	Share
CU6	Clarity and Cardinal Health enter into Agreement for TCT		02/12/21	382.02KB	Share
CU6	Fifty percent recruitment milestone for PROPELLER trial		01/12/21	511.44KB	Share
CU6	Clarity strengthens patent protection of SAR-bisPSMA		26/11/21	394.8KB	Share
CU6	Results of Meeting		25/11/21	425.14KB	Share
CU6	Managing Directors Presentation to Annual General Meeting	PRICE SENSITIVE	25/11/21	2.41MB	Share
CU6	Chairman's Address to Shareholders	PRICE SENSITIVE	25/11/21	398.78KB	Share
CU6	Quarterly Activity Report	PRICE SENSITIVE	18/11/21	414.77KB	Share
CU6	Clarity Presentation for Bell Potter Healthcare conference		10/11/21	4.03MB	Share
CU6	Dosimetry Recruitment of theranostic prostate trial complete	PRICE SENSITIVE	10/11/21	576.07KB	Share
CU6	Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/10/21	541.35KB	Share
CU6	Notice of Annual General Meeting/Proxy Form		22/10/21	2.46MB	Share
CU6	Annual Report to shareholders		22/10/21	4.21MB	Share
CU6	Recruitment closed on C-BOBCAT SAR-Bombesin trial	PRICE SENSITIVE	19/10/21	384.13KB	Share
CU6	Manufacturing agreement for Clarity's US clinical trials		30/09/21	416.16KB	Share
CU6	Notice of Annual General Meeting		29/09/21	356.41KB	Share
CU6	Clarity joins the CORAR		22/09/21	366.92KB	Share
CU6	Release of securities from escrow		21/09/21	384.12KB	Share
CU6	Becoming a substantial holder - GenesisCare		02/09/21	569.45KB	Share
CU6	Company Briefing		01/09/21	4.16MB	Share
CU6	Becoming a substantial holder - Taylor		30/08/21	485KB	Share
CU6	Becoming a substantial holder - Morgan		30/08/21	493.55KB	Share
CU6	Becoming a substantial holder - Cabbit Pty Ltd		30/08/21	91.71KB	Share
CU6	Becoming a substantial holder - Harris		30/08/21	1.23MB	Share
CU6	Becoming a substantial holder - TM Ventures		30/08/21	1.32MB	Share
CU6	App 3X Initial Director's Interest Notice - all directors		26/08/21	466.19KB	Share
CU6	App 4E Preliminary Final Report 30 June 2021	PRICE SENSITIVE	25/08/21	1.52MB	Share
CU6	First patient treated in theranostic prostate cancer trial		25/08/21	162.63KB	Share
CU6	Clarity Pharmaceuticals lists on the ASX		25/08/21	435.29KB	Share
CU6	Pre-Quotation Disclosure Statement		24/08/21	389.8KB	Share
CU6	Top 20 Shareholders		24/08/21	12.97KB	Share
CU6	Distribution Schedule		24/08/21	9.85KB	Share
CU6	Corporate Governance Statement		24/08/21	198.94KB	Share

CU6 50% recruitment milestone reached for prostate cancer trial
27/10/22	PRICE SENSITIVE	311.17KB	Share
CU6 Notice of Annual General Meeting/Proxy Form
25/10/22		1.55MB	Share
CU6 Application for quotation of securities - CU6
13/10/22		25.78KB	Share
CU6 Notification of cessation of securities - CU6
12/10/22		22.96KB	Share
CU6 First patient treated in therapeutic prostate cancer trial
07/10/22	PRICE SENSITIVE	689.22KB	Share
CU6 First participant imaged in Phase II SAR-Bombesin trial
06/10/22	PRICE SENSITIVE	323.81KB	Share
CU6 Date of AGM
30/09/22		153.07KB	Share
CU6 Corporate Governance Annual Statement
15/09/22		824.96KB	Share
CU6 Annual Report to shareholders
15/09/22		14.36MB	Share
CU6 First participants imaged in SAR-Bombesin trial
14/09/22	PRICE SENSITIVE	319.77KB	Share
CU6 Radiopharmaceuticals Expert Joins Clarity as Chief Scientifi
13/09/22		197.96KB	Share
CU6 Clarity strengthens protection of the SAR-bisPSMA product
12/09/22		298.39KB	Share
CU6 Recruitment opens for Phase II trial in Prostate Cancer
05/09/22	PRICE SENSITIVE	334.84KB	Share
CU6 Preliminary Final Report
24/08/22	PRICE SENSITIVE	3.52MB	Share
CU6 Paediatric neuroblastoma trial advances to cohort 3
23/08/22	PRICE SENSITIVE	194.47KB	Share
CU6 Imaging trial in prostate cancer opens for recruitment
22/08/22	PRICE SENSITIVE	293.07KB	Share
CU6 Notification regarding unquoted securities - CU6
16/08/22		29.21KB	Share
CU6 Clarity expands manufacturing capabilities
11/08/22		172.73KB	Share
CU6 Clarity and Evergreen expand TCT manufacturing
09/08/22		181.89KB	Share
CU6 Quarterly Activities/Appendix 4C Cash Flow Report
27/07/22	PRICE SENSITIVE	6.99MB	Share
CU6 Recruitment complete for diagnostic prostate cancer trial
20/07/22		663.89KB	Share
CU6 Notification of cessation of securities - CU6
07/07/22		21.69KB	Share
CU6 Change of Director's Interest Notice - Biggin
06/07/22		218.19KB	Share
CU6 Notification regarding unquoted securities - CU6
06/07/22		24.87KB	Share
CU6 Application for quotation of securities - CU6
06/07/22		25.12KB	Share
CU6 Application for quotation of securities - CU6
29/06/22		25.12KB	Share
CU6 Leading Australian cancer expert joins Clarity SAB
29/06/22		181.29KB	Share
CU6 Change of Director's Interest Notice O'Bryan-Tear
23/06/22		214.64KB	Share
CU6 Application for quotation of securities - CU6
22/06/22		25.91KB	Share
CU6 Release of Securities from Escrow
20/06/22		168.71KB	Share
CU6 Governance & Trading Policy Update
09/06/22		366.57KB	Share
CU6 IND Approval by US FDA for Phase II SAR-Bombesin trial
06/06/22	PRICE SENSITIVE	311.92KB	Share
CU6 Notification regarding unquoted securities - CU6
01/06/22		28.46KB	Share
CU6 Change of Director's Interest Notice - Thomas Ramdahl
01/06/22		214.18KB	Share
CU6 Change of Director's Interest Notice - Rob Thomas
31/05/22		212.77KB	Share
CU6 Clarity adds innovative nanobody IP
31/05/22		164.73KB	Share
CU6 Presentation Jefferies Biotech Summit
27/05/22	PRICE SENSITIVE	3.43MB	Share
CU6 Dr Neal Shore joins Clarity's CAB
26/05/22		160.38KB	Share
CU6 Clarity confirms no supply issues to its clinical trials
10/05/22		174.34KB	Share
CU6 Quarterly Activities/Appendix 4C Cash Flow Report
29/04/22	PRICE SENSITIVE	6.73MB	Share
CU6 Cleansing Notice
21/04/22		182.51KB	Share
CU6 Application for quotation of securities - CU6
21/04/22		24.93KB	Share
CU6 First patient treated in the prostate cancer imaging trial
21/04/22	PRICE SENSITIVE	292.05KB	Share
CU6 Application for quotation of securities - CU6
14/04/22		25.7KB	Share
CU6 Notification of cessation of securities - CU6
14/04/22		22.47KB	Share
CU6 Dr Andrei Iagaru joins Clarity Scientific Advisory Board
05/04/22		158.74KB	Share
CU6 Appointment of CFO
04/04/22		156.75KB	Share
CU6 COBRA trial in prostate cancer opens for recruitment
28/03/22		202.62KB	Share
CU6 New clinical trial collaboration in prostate cancer
24/03/22		190.28KB	Share
CU6 Clarity - Investor Presentation 03-03-2022
03/03/22		4.37MB	Share
CU6 Clarity Half Yearly Report
28/02/22	PRICE SENSITIVE	7.02MB	Share
CU6 Half Year Accounts
28/02/22	PRICE SENSITIVE	1.35MB	Share
CU6 Update on China Grand Pharmaceutical and Healthcare Holdings
28/02/22	PRICE SENSITIVE	159.86KB	Share
CU6 First patient treated in cohort 2 neuroblastoma trial
25/02/22	PRICE SENSITIVE	184.55KB	Share
CU6 Release of Securities from Escrow
18/02/22		179.15KB	Share
CU6 US FDA Study May Proceed letter for Cu-64 SAR-bisPSMA
07/02/22	PRICE SENSITIVE	205.89KB	Share
CU6 Clarity receives $3.26 million R&D tax incentive refund
04/02/22	PRICE SENSITIVE	154.87KB	Share
CU6 Response to media reports of shortages of medical isotopes
03/02/22		185.69KB	Share
CU6 SARTATE Neuroblastoma trial advances to cohort 2
01/02/22	PRICE SENSITIVE	182.3KB	Share
CU6 Quarterly Activities/Appendix 4C Cash Flow Report
31/01/22	PRICE SENSITIVE	5.67MB	Share
CU6 Becoming a substantial holder
12/01/22		248.26KB	Share
CU6 Change of Director's Interest Notice - Biggin
04/01/22		218.35KB	Share
CU6 Cleansing Notice
04/01/22		398.42KB	Share
CU6 Application for quotation of securities - CU6
04/01/22		25.71KB	Share
CU6 Becoming a substantial holder
30/12/21		180.88KB	Share
CU6 Application for quotation of securities - CU6
30/12/21		25.92KB	Share
CU6 Application for quotation of securities - CU6
29/12/21		25.92KB	Share
CU6 Release of Securities from Escrow
07/12/21		395.43KB	Share
CU6 Clarity and Cardinal Health enter into Agreement for TCT
02/12/21		382.02KB	Share
CU6 Fifty percent recruitment milestone for PROPELLER trial
01/12/21		511.44KB	Share
CU6 Clarity strengthens patent protection of SAR-bisPSMA
26/11/21		394.8KB	Share
CU6 Results of Meeting
25/11/21		425.14KB	Share
CU6 Managing Directors Presentation to Annual General Meeting
25/11/21	PRICE SENSITIVE	2.41MB	Share
CU6 Chairman's Address to Shareholders
25/11/21	PRICE SENSITIVE	398.78KB	Share
CU6 Quarterly Activity Report
18/11/21	PRICE SENSITIVE	414.77KB	Share
CU6 Clarity Presentation for Bell Potter Healthcare conference
10/11/21		4.03MB	Share
CU6 Dosimetry Recruitment of theranostic prostate trial complete
10/11/21	PRICE SENSITIVE	576.07KB	Share
CU6 Appendix 4C Cash Flow Report
27/10/21	PRICE SENSITIVE	541.35KB	Share
CU6 Notice of Annual General Meeting/Proxy Form
22/10/21		2.46MB	Share
CU6 Annual Report to shareholders
22/10/21		4.21MB	Share
CU6 Recruitment closed on C-BOBCAT SAR-Bombesin trial
19/10/21	PRICE SENSITIVE	384.13KB	Share
CU6 Manufacturing agreement for Clarity's US clinical trials
30/09/21		416.16KB	Share
CU6 Notice of Annual General Meeting
29/09/21		356.41KB	Share
CU6 Clarity joins the CORAR
22/09/21		366.92KB	Share
CU6 Release of securities from escrow
21/09/21		384.12KB	Share
CU6 Becoming a substantial holder - GenesisCare
02/09/21		569.45KB	Share
CU6 Company Briefing
01/09/21		4.16MB	Share
CU6 Becoming a substantial holder - Taylor
30/08/21		485KB	Share
CU6 Becoming a substantial holder - Morgan
30/08/21		493.55KB	Share
CU6 Becoming a substantial holder - Cabbit Pty Ltd
30/08/21		91.71KB	Share
CU6 Becoming a substantial holder - Harris
30/08/21		1.23MB	Share
CU6 Becoming a substantial holder - TM Ventures
30/08/21		1.32MB	Share
CU6 App 3X Initial Director's Interest Notice - all directors
26/08/21		466.19KB	Share
CU6 App 4E Preliminary Final Report 30 June 2021
25/08/21	PRICE SENSITIVE	1.52MB	Share
CU6 First patient treated in theranostic prostate cancer trial
25/08/21		162.63KB	Share
CU6 Clarity Pharmaceuticals lists on the ASX
25/08/21		435.29KB	Share
CU6 Pre-Quotation Disclosure Statement
24/08/21		389.8KB	Share
CU6 Top 20 Shareholders
24/08/21		12.97KB	Share
CU6 Distribution Schedule
24/08/21		9.85KB	Share
CU6 Corporate Governance Statement
24/08/21		198.94KB	Share

REFRESH

First 2 3 4

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $3.61		Change 0.180(5.25%)		Mkt cap ! $1.340B

Open	High	Low	Value	Volume
$3.52	$3.72	$3.46	$14.55M	4.024M

Buyers (Bids)

No.	Vol.	Price($)
7	28663	$3.61

Sellers (Offers)

Price($)	Vol.	No.
$3.62	26835	3

View Market Depth

No.	Vol.	Price($)
1	5000	4.000
1	2000	3.950
1	248	3.830
11	26482	3.800
2	19337	3.790

Price($)	Vol.	No.
3.270	10000	1
3.390	226	2
3.400	597	2
3.420	16044	7
3.430	8439	3

Last trade - 16.10pm 13/08/2025 (20 minute delay)


Last $3.63		Change 0.180 ( 6.09 %)
Open	High	Low	Volume
$3.56	$3.71	$3.47	542092
Last updated 15.59pm 13/08/2025 ?

CU6 (ASX) Chart

CLARITY PHARMACEUTICALS LTD - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories